http://www.iii.co.uk/investment/detail?code=cotn:VEC.L&display=news http://www.iii.co.uk/investment/detail?code=cotn:VEC.L&display=news&action=article&articleid=8588981&from=rss RNS Number : 5283DVectura Group plc17 May 2012   NVA237 Phase III data showed rapid, sustained improvement in lung function and symptom relief over one year in COPD patients   ·     GLOW2 study showed NVA237 superior to placebo and similar to OL tiotropium in increasing... Thu, 17 May 2012 07:00:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:VEC.L&display=news&action=article&articleid=8575425&from=rss RNS Number : 6121CVectura Group plc03 May 2012   Vectura's Chief Operations Officer appointed to the Board     Chippenham, UK - 3 May 2012: Vectura Group plc (LSE: VEC) ("Vectura"), which specialises in developing therapies, principally for the treatment of respiratory... Thu, 03 May 2012 07:00:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:VEC.L&display=news&action=article&articleid=8572530&from=rss RNS Number : 4120CVectura Group plc01 May 2012   Vectura Group plc (the "Company")   VOTING RIGHTS AND CAPITAL     Chippenham, UK, 1 May 2012: In accordance with the Financial Service Authority's Transparency Directive, Transitional Provision 6, Vectura Group... Tue, 01 May 2012 07:00:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:VEC.L&display=news&action=article&articleid=8567748&from=rss RNS Number : 0932CVectura Group plc26 April 2012   Vectura Group plc - Preliminary Results ======================================= - Strong financial performance with multiple catalysts ahead - ============================================================== Chippenham,... Thu, 26 Apr 2012 07:00:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:VEC.L&display=news&action=article&articleid=8564956&from=rss RNS Number : 9184BVectura Group plc24 April 2012   QVA149 ILLUMINATE Phase III COPD study meets primary endpoint and clarification of anticipated timing of US filings for NVA237 and QVA149   ·     Superior lung function with once-daily QVA149 compared with twice-daily... Tue, 24 Apr 2012 07:00:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:VEC.L&display=news&action=article&articleid=8552240&from=rss RNS Number : 0642BVectura Group plc11 April 2012   Notice of Results     Chippenham, UK - 11 April, 2012: Vectura Group plc (LSE: VEC), the Company that specialises in developing inhaled therapies for the treatment of respiratory diseases, will be announcing its preliminary ... Wed, 11 Apr 2012 07:00:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:VEC.L&display=news&action=article&articleid=8544629&from=rss RNS Number : 5495AVectura Group plc02 April 2012   QVA149 phase III COPD studies met primary endpoints   ·     Efficacy, safety and exercise endurance primary endpoints all met   ·     Studies are part of IGNITE Phase III clinical trial program intended to form the... Mon, 02 Apr 2012 07:00:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:VEC.L&display=news&action=article&articleid=8544408&from=rss RNS Number : 4116AVectura Group plc02 April 2012   Vectura Group plc (the "Company")   VOTING RIGHTS AND CAPITAL     Chippenham, UK, 2 April 2012: In accordance with the Financial Service Authority's Transparency Directive, Transitional Provision 6, Vectura Group... Mon, 02 Apr 2012 07:00:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:VEC.L&display=news&action=article&articleid=8513938&from=rss RNS Number : 4811YVectura Group plc01 March 2012   Vectura Group plc (the "Company")   VOTING RIGHTS AND CAPITAL     Chippenham, UK, 1 March 2012: In accordance with the Financial Service Authority's Transparency Directive, Transitional Provision 6, Vectura Group... Thu, 01 Mar 2012 10:56:00 GMT